| 000 | 01142 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250515011607.0 | ||
| 264 | 0 | _c20060314 | |
| 008 | 200603s 0 0 eng d | ||
| 022 | _a1744-764X | ||
| 024 | 7 |
_a10.1517/14740338.5.1.9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBratcher, Jason M | |
| 245 | 0 | 0 |
_aToxicity of infliximab in the course of treatment of Crohn's disease. _h[electronic resource] |
| 260 |
_bExpert opinion on drug safety _cJan 2006 |
||
| 300 |
_a9-16 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 |
_aLupus Vulgaris _xchemically induced |
| 650 | 0 | 4 |
_aLymphoma _xchemically induced |
| 650 | 0 | 4 |
_aTuberculosis _xchemically induced |
| 700 | 1 | _aKorelitz, Burton I | |
| 773 | 0 |
_tExpert opinion on drug safety _gvol. 5 _gno. 1 _gp. 9-16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14740338.5.1.9 _zAvailable from publisher's website |
| 999 |
_c15989878 _d15989878 |
||